About PROMETHERA^® Biosciences

Promethera^® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.

Promethera^® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Promethera^® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

• Promethera^® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver pathologies that can be addressed with the same product.
• Promethera^® HepaScreen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. The cell model is designed for the discovery and pre-clinical evaluation of new chemical entities.

Promethera^® Biosciences was founded in 2009 by Sopartec SA, the technology transfer company for the Université Catholique de Louvain and Professor Etienne Sokal, a leading expert in hepatology and cell therapy. In May 2009, Eric Halioua became the Chief Executive Officer of Promethera^® Biosciences.

End of October 2009, Promethera^® Biosciences has completed a 5.3 million euros A-round of funding. The round has been complemented by more than 4 million euros of grants and loans from the Walloon Region.